The METABRIC database also revealed that higher concurrent expression of CD147 and CD276 was associated with unfavorable survival outcomes in HER2+ BC patients who received chemotherapy, both for DFS and OS (p = 0.04 and 0.08, respectively) (Fig. 5d). The gene discussed is CD276; the disease is breast cancer.